Journal Title:
Clinical Lymphoma , Myeloma & Leukemia
Original Publication Date:
Jun 2020
Bone Marrow Disease(s):
To Target the Untargetable: Elucidation of Synergy of APR-246 and Azacitidine in TP53 Mutant Myelodysplastic Syndromes and Acute Myeloid Leukemia
Journal Title:
Haematologica
Original Publication Date:
Jun 2020
Bone Marrow Disease(s):
Rigosertib in Combination With Azacitidine in Patients With Myelodysplastic Syndromes or Acute Myeloid Leukemia: Results of a Phase 1 Study
Journal Title:
Leukemia Research
Original Publication Date:
Jul 2020
Bone Marrow Disease(s):
Iron Overload Alters the Energy Metabolism in Patients With Myelodysplastic Syndromes: Results From the Multicenter FISM BIOFER Study
Journal Title:
Scientific Reports
Original Publication Date:
Jun 2020
Bone Marrow Disease(s):
Myelodysplastic Syndromes: A Review of Therapeutic Progress Over the Past 10 Years
Journal Title:
Expert Review of Anticancer Therapy
Original Publication Date:
Jun 2020
Bone Marrow Disease(s):
In Search for a Haemoglobin Threshold in Myelodysplastic Syndromes
Journal Title:
British Journal of Haematology
Original Publication Date:
Jun 2020
Bone Marrow Disease(s):
High Serum Ferritin Levels in Newly Diagnosed Patients With Myelodysplastic Syndromes Are Associated With Greater Symptom Severity
Journal Title:
International Journal of Hematology
Original Publication Date:
Jun 2020
Bone Marrow Disease(s):
Wide Variation in Use and Interpretation of Gene Mutation Profiling Panels Among Health Care Providers of Patients With Myelodysplastic Syndromes: Results of a Large Web-Based Survey
Journal Title:
Leukemia & Lymphoma
Original Publication Date:
Jun 2020
Next-generation sequencing (NGS) is increasingly employed for diagnosis, risk stratification, and management of patients with myelodysplastic syndrome (MDS). We aimed to describe beliefs and practice patterns among providers who treat MDS patients with respect to the utility of NGS in diagnosis, risk stratification, prognosis, and treatment decisions at various points along the disease trajectory, response assessment, and development of institutional guidelines for MDS-specific molecular profiling.
Bone Marrow Disease(s):
Venetoclax and Hypomethylating Agents (HMAs) Induce High Response Rates in MDS, Including Patients After HMA Therapy Failure
Journal Title:
Blood Advances
Original Publication Date:
Jul 2020
Bone Marrow Disease(s):
Where There's Smoke, There's Fire: Inflammation Drives MDS
Journal Title:
Trends in immunology
Original Publication Date:
Jul 2020
Bone Marrow Disease(s):